Almost 90% of patients with metastatic castration-resistant prostate cancer have a clinically actionable genetic alteration, according to a recently published study. Among these patients, researchers found that 65% had genetic changes that could be targeted by investigational or FDA-approved drugs currently used for other cancers, leading to new individualized treatment strategies.